

**NCCN Non-Hodgkin's Lymphomas Guidelines V.4.2011 – Follow-up – 07/15/11**

Guidelines Page and Request	Panel Discussion	References	Vote		
			Yes	No	Abstain
<b>Peripheral T-Cell Lymphoma</b>					
<p><b>TCEL-B</b>  <b>Internal request:</b>                      Review the data for inclusion of brentuximab as a second-line suggested treatment regimen.</p> <p><b>External request:</b>                      Submitted by Seattle Genetics, Inc for inclusion of brentuximab vedotin as second-line therapy for patients with systemic anaplastic large cell lymphoma.</p>	<p>Based on the noted reference, the panel consensus was to list brentuximab as a second-line suggested treatment regimen for nodal anaplastic large cell lymphoma only.</p>	<p>Shustov AR, Advani R, Brice P, et al. Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma [abstract]. Blood 2010;116:Abstract 961.</p>	25	0	3